DYNAMIC PREDICTION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN NON-SMALL CELL LUNG CANCER (NSCLC) USING TUMOR SIZE: A LONGITUDINAL JOINT MODELING APPROACH.

被引：0
|
作者：
Al-Huniti, N. [1 ]
Onishchenko, D. [2 ]
Xu, H. [1 ]
Zhou, D. [1 ]
Masson, E. [1 ]
Helmlinger, G. [1 ]
Tomkinson, H. [3 ]
Abdallah, K. [4 ]
Dunyak, J. [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
[2] AstraZeneca, Moscow, Russia
[3] AstraZeneca, Cambridge, England
[4] AstraZeneca, Gaithersburg, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-004
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [1] Joint model of longitudinal tumor size and overall survival (OS) in non-small cell lung cancer (NSCLC): A Bayesian approach
    Al-Huniti, Nidal
    Xu, Hongmei
    Zhou, Diansong
    Edlund, Helena
    Aksenov, Sergey
    Helmlinger, Gabriel
    Dunyak, James
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [2] Bayesian formulation of a joint model of longitudinal tumor size and overall survival (OS) in Non-Small Cell Lung Cancer (NSCLC)
    Al-Huniti, Nidal
    Dunyak, James
    Aksenov, Sergey
    Zhou, Diansong
    Xu, Hongmei
    Masson, Eric
    Helmlinger, Gabriel
    Edlund, Helena
    Stanski, Donald
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S141 - S141
  • [3] Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)
    Onishchenko, Dmitry
    Dunyak, James
    Masson, Eric
    Helmlinger, Gabriel
    Peskov, Kirill
    Tomkinson, Helen
    Stanski, Donald
    Al-Huniti, Nidal
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S138 - S138
  • [4] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Prediction of progression free survival using tumor dynamics in non-small cell lung cancer (NSCLC) patients
    Tong, Xiao
    Dunyak, James
    Zhou, Diansong
    Onishchenko, Dmitry
    Carlile, David J.
    Tomkinson, Helen
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    Xu, Hongmei
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S45 - S45
  • [6] Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients
    Tong, Xiao
    Dunyak, James
    Zhou, Diansong
    Carlile, David
    Tomkinson, Helen
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    Xu, Hongmei
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [7] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, Louise
    Chouaid, Christos
    Vergnenegre, Alain
    Bischoff, Helge
    Walzer, Stefan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1447 - S1448
  • [8] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [9] VALUE OF PROGRESSION-FREE SURVIVAL (PFS) IN REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC): AN EXPLORATORY MODELING ANALYSIS
    Ferrufino, C. P.
    Foley, D.
    Trochlil, K.
    Munakata, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A447 - A447
  • [10] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345